Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | $12.00 | Outperform | Mizuho |
| 2/10/2025 | $11.00 | Outperform | Wedbush |
| 12/20/2024 | $9.00 | Overweight | Wells Fargo |
| 12/19/2024 | $7.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 9/9/2024 | $7.00 → $8.00 | Outperform | Leerink Partners |
| 6/13/2024 | $8.00 | Buy | Rodman & Renshaw |
| 10/10/2023 | $10.00 | Outperform | Wedbush |
| 2/28/2022 | $6.50 → $6.00 | Buy | HC Wainwright & Co. |
8-K - MANNKIND CORP (0000899460) (Filer)
8-K - MANNKIND CORP (0000899460) (Filer)
144 - MANNKIND CORP (0000899460) (Subject)
Mizuho initiated coverage of Mannkind with a rating of Outperform and set a new price target of $12.00
Wedbush initiated coverage of Mannkind with a rating of Outperform and set a new price target of $11.00
Wells Fargo initiated coverage of Mannkind with a rating of Overweight and set a new price target of $9.00
SC 13G/A - MANNKIND CORP (0000899460) (Subject)
SC 13G/A - MANNKIND CORP (0000899460) (Subject)
SC 13G/A - MANNKIND CORP (0000899460) (Subject)
MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind's CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. ("Thirona") with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.